Table 1.
Patient Clinical Characteristics and Histologic Findings
| Characteristics and Histologic Features | Overall (119) | Low-Risk Group (34) | Medium-Risk Group (59) | High-Risk Group (26) | P |
|---|---|---|---|---|---|
| Age, y | 63 (46-69) | 63 (44-67) | 65 (57-73) | 59 (51-71) | 0.16a |
| Female sex | 63 (53%) | 18 (53%) | 32 (54%) | 13 (50%) | 0.94b |
| eGFR at diagnosis, mL/min/1.73 m2 | 22.5 (12-34) | 43 (29-61) | 21 (11-29) | 14 (10-23) | <0.001a |
| ANCA antibody type | 0.62b | ||||
| MPO, n (%) | 64 (54%) | 18 (53%) | 29 (49%) | 17 (65%) | |
| PR3, n (%) | 47 (40%) | 16 (47%) | 26 (44%) | 5 (19%) | |
| Negative | 8 (6%) | 0 (0%) | 4 (7%) | 4 (15%) | |
| Normal glomeruli (N) | 27 (10-56.5) | 60 (50-71) | 28 (20-50) | 6 (0-10) | <0.001a |
| IFTA > 25% | 47 (40%) | 0 (0%) | 28 (47%) | 19 (73%) | <0.001b |
| Risk score | 3 (0-7) | 0 (0-0) | 3 (2-5) | 9 (8-9) | <0.001a |
Note: Values expressed as median (interquartile range) or number (percent).
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; eGFR, estimated glomerular filtration rate by the Modification of Diet in Renal Disease Study equation; IFTA, interstitial fibrosis and tubular atrophy; MPO, myeloperoxidase; PR3, proteinase 3.
a
Analysis of variance test
b
χ2.